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Antimicrobial resistance (AMR) has received significant attention in recent years. As bacteria evolve 
to resist the effects of existing antibiotics, infections become more difficult to treat and modern 
medical interventions become more dangerous to perform.  Fear of so-called “superbugs” has 
spurred international authorities into action. In 2011, the World Health Organization (WHO) 
developed a European Strategic Action Plan on Antibiotic Resistance, which set forth strategic 
objectives to aid European Member States in addressing the complex factors that drive AMR1. In 
response, both the European Commission (EC) and the United Kingdom (UK) devised their own 
strategies to meet these objectives.  
In 2011, the EC published its Action Plan, “Against the rising threats from Antimicrobial Resistance”, 
which laid out 12 recommendations for its Member States to implement2. This was accompanied in 
2013 by a Road Map document detailing specific activities and milestones to satisfy each of the 
Plan’s recommendations; this was updated in 2016 to reflect an evaluation of the Plan3,4. The UK 
replaced its existing AMR Action Plan from 2000 with a new and improved Five Year Antimicrobial 
Resistance Strategy 2013-20185,6. This strategy went beyond that of the EU, incorporating aims to 
increase awareness, promote stewardship of current therapies, and stimulate the development of 
new treatments. These strategies were met with enthusiasm by the global community and certain 
objectives have been implemented beyond European borders. In 2011, the Transatlantic Taskforce 
on Antimicrobial Resistance (TATFAR) was established to improve collaboration between Europe and 
North America7. 
With mounting political pressure for countries to address AMR, we critically appraised and evaluated 
the extent to which the recommendations of the UK and EU strategies have been implemented and 
produced a report for the UK All Party Parliamentary Group on Antibiotics8,9. We did not review the 
2015 WHO Global Action Plan on AMR or the 2017 European One Health Action Plan Against AMR as 
the objectives of the Global Plan are too general and the EU has not had sufficient time to address 
the EU One Health Plan9,10.  
Except for three key areas, the available evidence suggests that the UK and many EU member states 
have been successful in implementing the AMR strategies. There was a lack of evidence indicating 
significant activity to regulate and restrict non-prescription use of critically important antibiotics in 
humans, animals, and agriculture, both among EU countries and within the UK. Likewise, it appears 
that little has been done to evaluate the need for incentives to stimulate research and development 
of veterinary medicines. Finally, all regions appear to have struggled to address the 
recommendations regarding education and awareness. This lack of progress could be due to 
unsatisfactory action by regional and national authorities and/or a lack of tangible outcomes by 
which to measure success.  
To facilitate collaboration and accountability, the language used throughout the various documents 
should be improved. The strategies employ vague recommendations and many lack measureable 
targets and objectives. The subjective terminology, such as “improve” and “promote”, used 
throughout all strategies may have limited the impetus for definitive action by governments and 
delegated authorities. This is because it allows them to ‘tick boxes’ with no requirement to evaluate 
the intervention’s success.  Without measureable targets it is unrealistic to expect that governments 
will invest the necessary funds to deliver interventions with impact. Even if they do, it is difficult to 
identify evidence of this impact, or even of the activity itself. There is also inconsistency between the 
strategies themselves in regards to terminology, compliance areas, and recommendations, making it 
difficult to discern whether the EU and UK regional action plans have successfully satisfied the 
overarching WHO Action Plan.  
The UK and other EU Member States have made progress in addressing AMR by meeting the 
majority of the AMR Strategy recommendations, which in turn satisfy those of the WHO-Europe 
Plan. However, to facilitate collaboration and coordination these strategies should be harmonised. 
Further activity to satisfy both of these plans is also recommended. First, a review into the progress 
of discovery, research, and development of new human and veterinary treatments including new 
drugs should be coordinated. Second, review on restrictions on the use of last resort antibiotics in 
veterinary medicine should be continued. Third, a compendium of harmonised educational tools on 
AMR should be developed. Finally, there should be careful evaluation of the efficacy of educational 
campaigns. 
In summary, the UK and other European countries have made progress in addressing the complex 
issues of AMR. We look forward to the outcomes of upcoming G20 discussions and the new WHO 
AMR Strategy and hope to see greater regulation and increased accountability in future regional and 
national strategies through SMART (specific, measurable, attainable, realistic, and timely) objectives 
that clearly demonstrate compliance with the WHO Action Plan.  
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